Report cover image

Global Virus like Particle (VLP) Vaccines Industry Growth and Trends Forecast to 2031

Publisher APO Research, Inc.
Published Jul 07, 2025
Length 103 Pages
SKU # APRC20340007

Description

Summary

According to APO Research, The global Virus like Particle (VLP) Vaccines market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for Virus like Particle (VLP) Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for Virus like Particle (VLP) Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for Virus like Particle (VLP) Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global manufacturers of Virus like Particle (VLP) Vaccines include WuXi Biologics, Junshi Biosciences, Luye Pharma Group, Chengdu Kanghua Biological Products Co., Ltd., Shanghai Bovax Biotechnology Co., Ltd., VBI Vaccines Inc, Premas Biotech, Creative Diagnostics and Creative Biostructure, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Virus like Particle (VLP) Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Virus like Particle (VLP) Vaccines.

The Virus like Particle (VLP) Vaccines market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Virus like Particle (VLP) Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Virus like Particle (VLP) Vaccines Segment by Company

WuXi Biologics
Junshi Biosciences
Luye Pharma Group
Chengdu Kanghua Biological Products Co., Ltd.
Shanghai Bovax Biotechnology Co., Ltd.
VBI Vaccines Inc
Premas Biotech
Creative Diagnostics
Creative Biostructure
Coriolis
Charles River Laboratories
BioAgilytix
AstraZeneca Group (Icosavax)
Virus like Particle (VLP) Vaccines Segment by Type

Prophylactic Vaccine
Therapeutic Vaccine
Virus like Particle (VLP) Vaccines Segment by Application

Human Papillomavirus (HPV)
Hepatitis E Virus (HEV)
Hepatitis B Virus (HBV)
Other
Virus like Particle (VLP) Vaccines Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Virus like Particle (VLP) Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Virus like Particle (VLP) Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Virus like Particle (VLP) Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Virus like Particle (VLP) Vaccines manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Virus like Particle (VLP) Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

103 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Virus like Particle (VLP) Vaccines Market Size Estimates and Forecasts (2020-2031)
1.2.2 Global Virus like Particle (VLP) Vaccines Sales Estimates and Forecasts (2020-2031)
1.3 Virus like Particle (VLP) Vaccines Market by Type
1.3.1 Prophylactic Vaccine
1.3.2 Therapeutic Vaccine
1.4 Global Virus like Particle (VLP) Vaccines Market Size by Type
1.4.1 Global Virus like Particle (VLP) Vaccines Market Size Overview by Type (2020-2031)
1.4.2 Global Virus like Particle (VLP) Vaccines Historic Market Size Review by Type (2020-2025)
1.4.3 Global Virus like Particle (VLP) Vaccines Forecasted Market Size by Type (2026-2031)
1.5 Key Regions Market Size by Type
1.5.1 North America Virus like Particle (VLP) Vaccines Sales Breakdown by Type (2020-2025)
1.5.2 Europe Virus like Particle (VLP) Vaccines Sales Breakdown by Type (2020-2025)
1.5.3 Asia-Pacific Virus like Particle (VLP) Vaccines Sales Breakdown by Type (2020-2025)
1.5.4 South America Virus like Particle (VLP) Vaccines Sales Breakdown by Type (2020-2025)
1.5.5 Middle East and Africa Virus like Particle (VLP) Vaccines Sales Breakdown by Type (2020-2025)
2 Global Market Dynamics
2.1 Virus like Particle (VLP) Vaccines Industry Trends
2.2 Virus like Particle (VLP) Vaccines Industry Drivers
2.3 Virus like Particle (VLP) Vaccines Industry Opportunities and Challenges
2.4 Virus like Particle (VLP) Vaccines Industry Restraints
3 Market Competitive Landscape by Company
3.1 Global Top Players by Virus like Particle (VLP) Vaccines Revenue (2020-2025)
3.2 Global Top Players by Virus like Particle (VLP) Vaccines Sales (2020-2025)
3.3 Global Top Players by Virus like Particle (VLP) Vaccines Price (2020-2025)
3.4 Global Virus like Particle (VLP) Vaccines Industry Company Ranking, 2023 VS 2024 VS 2025
3.5 Global Virus like Particle (VLP) Vaccines Major Company Production Sites & Headquarters
3.6 Global Virus like Particle (VLP) Vaccines Company, Product Type & Application
3.7 Global Virus like Particle (VLP) Vaccines Company Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Virus like Particle (VLP) Vaccines Market CR5 and HHI
3.8.2 Global Top 5 and 10 Virus like Particle (VLP) Vaccines Players Market Share by Revenue in 2024
3.8.3 2023 Virus like Particle (VLP) Vaccines Tier 1, Tier 2, and Tier 3
4 Virus like Particle (VLP) Vaccines Regional Status and Outlook
4.1 Global Virus like Particle (VLP) Vaccines Market Size and CAGR by Region: 2020 VS 2024 VS 2031
4.2 Global Virus like Particle (VLP) Vaccines Historic Market Size by Region
4.2.1 Global Virus like Particle (VLP) Vaccines Sales in Volume by Region (2020-2025)
4.2.2 Global Virus like Particle (VLP) Vaccines Sales in Value by Region (2020-2025)
4.2.3 Global Virus like Particle (VLP) Vaccines Sales (Volume & Value), Price and Gross Margin (2020-2025)
4.3 Global Virus like Particle (VLP) Vaccines Forecasted Market Size by Region
4.3.1 Global Virus like Particle (VLP) Vaccines Sales in Volume by Region (2026-2031)
4.3.2 Global Virus like Particle (VLP) Vaccines Sales in Value by Region (2026-2031)
4.3.3 Global Virus like Particle (VLP) Vaccines Sales (Volume & Value), Price and Gross Margin (2026-2031)
5 Virus like Particle (VLP) Vaccines by Application
5.1 Virus like Particle (VLP) Vaccines Market by Application
5.1.1 Human Papillomavirus (HPV)
5.1.2 Hepatitis E Virus (HEV)
5.1.3 Hepatitis B Virus (HBV)
5.1.4 Other
5.2 Global Virus like Particle (VLP) Vaccines Market Size by Application
5.2.1 Global Virus like Particle (VLP) Vaccines Market Size Overview by Application (2020-2031)
5.2.2 Global Virus like Particle (VLP) Vaccines Historic Market Size Review by Application (2020-2025)
5.2.3 Global Virus like Particle (VLP) Vaccines Forecasted Market Size by Application (2026-2031)
5.3 Key Regions Market Size by Application
5.3.1 North America Virus like Particle (VLP) Vaccines Sales Breakdown by Application (2020-2025)
5.3.2 Europe Virus like Particle (VLP) Vaccines Sales Breakdown by Application (2020-2025)
5.3.3 Asia-Pacific Virus like Particle (VLP) Vaccines Sales Breakdown by Application (2020-2025)
5.3.4 South America Virus like Particle (VLP) Vaccines Sales Breakdown by Application (2020-2025)
5.3.5 Middle East and Africa Virus like Particle (VLP) Vaccines Sales Breakdown by Application (2020-2025)
6 Company Profiles
6.1 WuXi Biologics
6.1.1 WuXi Biologics Comapny Information
6.1.2 WuXi Biologics Business Overview
6.1.3 WuXi Biologics Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.1.4 WuXi Biologics Virus like Particle (VLP) Vaccines Product Portfolio
6.1.5 WuXi Biologics Recent Developments
6.2 Junshi Biosciences
6.2.1 Junshi Biosciences Comapny Information
6.2.2 Junshi Biosciences Business Overview
6.2.3 Junshi Biosciences Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Junshi Biosciences Virus like Particle (VLP) Vaccines Product Portfolio
6.2.5 Junshi Biosciences Recent Developments
6.3 Luye Pharma Group
6.3.1 Luye Pharma Group Comapny Information
6.3.2 Luye Pharma Group Business Overview
6.3.3 Luye Pharma Group Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Luye Pharma Group Virus like Particle (VLP) Vaccines Product Portfolio
6.3.5 Luye Pharma Group Recent Developments
6.4 Chengdu Kanghua Biological Products Co., Ltd.
6.4.1 Chengdu Kanghua Biological Products Co., Ltd. Comapny Information
6.4.2 Chengdu Kanghua Biological Products Co., Ltd. Business Overview
6.4.3 Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Product Portfolio
6.4.5 Chengdu Kanghua Biological Products Co., Ltd. Recent Developments
6.5 Shanghai Bovax Biotechnology Co., Ltd.
6.5.1 Shanghai Bovax Biotechnology Co., Ltd. Comapny Information
6.5.2 Shanghai Bovax Biotechnology Co., Ltd. Business Overview
6.5.3 Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Product Portfolio
6.5.5 Shanghai Bovax Biotechnology Co., Ltd. Recent Developments
6.6 VBI Vaccines Inc
6.6.1 VBI Vaccines Inc Comapny Information
6.6.2 VBI Vaccines Inc Business Overview
6.6.3 VBI Vaccines Inc Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.6.4 VBI Vaccines Inc Virus like Particle (VLP) Vaccines Product Portfolio
6.6.5 VBI Vaccines Inc Recent Developments
6.7 Premas Biotech
6.7.1 Premas Biotech Comapny Information
6.7.2 Premas Biotech Business Overview
6.7.3 Premas Biotech Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Premas Biotech Virus like Particle (VLP) Vaccines Product Portfolio
6.7.5 Premas Biotech Recent Developments
6.8 Creative Diagnostics
6.8.1 Creative Diagnostics Comapny Information
6.8.2 Creative Diagnostics Business Overview
6.8.3 Creative Diagnostics Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Creative Diagnostics Virus like Particle (VLP) Vaccines Product Portfolio
6.8.5 Creative Diagnostics Recent Developments
6.9 Creative Biostructure
6.9.1 Creative Biostructure Comapny Information
6.9.2 Creative Biostructure Business Overview
6.9.3 Creative Biostructure Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Creative Biostructure Virus like Particle (VLP) Vaccines Product Portfolio
6.9.5 Creative Biostructure Recent Developments
6.10 Coriolis
6.10.1 Coriolis Comapny Information
6.10.2 Coriolis Business Overview
6.10.3 Coriolis Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Coriolis Virus like Particle (VLP) Vaccines Product Portfolio
6.10.5 Coriolis Recent Developments
6.11 Charles River Laboratories
6.11.1 Charles River Laboratories Comapny Information
6.11.2 Charles River Laboratories Business Overview
6.11.3 Charles River Laboratories Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Charles River Laboratories Virus like Particle (VLP) Vaccines Product Portfolio
6.11.5 Charles River Laboratories Recent Developments
6.12 BioAgilytix
6.12.1 BioAgilytix Comapny Information
6.12.2 BioAgilytix Business Overview
6.12.3 BioAgilytix Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.12.4 BioAgilytix Virus like Particle (VLP) Vaccines Product Portfolio
6.12.5 BioAgilytix Recent Developments
6.13 AstraZeneca Group (Icosavax)
6.13.1 AstraZeneca Group (Icosavax) Comapny Information
6.13.2 AstraZeneca Group (Icosavax) Business Overview
6.13.3 AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.13.4 AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Product Portfolio
6.13.5 AstraZeneca Group (Icosavax) Recent Developments
7 North America by Country
7.1 North America Virus like Particle (VLP) Vaccines Sales by Country
7.1.1 North America Virus like Particle (VLP) Vaccines Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.1.2 North America Virus like Particle (VLP) Vaccines Sales by Country (2020-2025)
7.1.3 North America Virus like Particle (VLP) Vaccines Sales Forecast by Country (2026-2031)
7.2 North America Virus like Particle (VLP) Vaccines Market Size by Country
7.2.1 North America Virus like Particle (VLP) Vaccines Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2.2 North America Virus like Particle (VLP) Vaccines Market Size by Country (2020-2025)
7.2.3 North America Virus like Particle (VLP) Vaccines Market Size Forecast by Country (2026-2031)
8 Europe by Country
8.1 Europe Virus like Particle (VLP) Vaccines Sales by Country
8.1.1 Europe Virus like Particle (VLP) Vaccines Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.1.2 Europe Virus like Particle (VLP) Vaccines Sales by Country (2020-2025)
8.1.3 Europe Virus like Particle (VLP) Vaccines Sales Forecast by Country (2026-2031)
8.2 Europe Virus like Particle (VLP) Vaccines Market Size by Country
8.2.1 Europe Virus like Particle (VLP) Vaccines Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2.2 Europe Virus like Particle (VLP) Vaccines Market Size by Country (2020-2025)
8.2.3 Europe Virus like Particle (VLP) Vaccines Market Size Forecast by Country (2026-2031)
9 Asia-Pacific by Country
9.1 Asia-Pacific Virus like Particle (VLP) Vaccines Sales by Country
9.1.1 Asia-Pacific Virus like Particle (VLP) Vaccines Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.1.2 Asia-Pacific Virus like Particle (VLP) Vaccines Sales by Country (2020-2025)
9.1.3 Asia-Pacific Virus like Particle (VLP) Vaccines Sales Forecast by Country (2026-2031)
9.2 Asia-Pacific Virus like Particle (VLP) Vaccines Market Size by Country
9.2.1 Asia-Pacific Virus like Particle (VLP) Vaccines Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2.2 Asia-Pacific Virus like Particle (VLP) Vaccines Market Size by Country (2020-2025)
9.2.3 Asia-Pacific Virus like Particle (VLP) Vaccines Market Size Forecast by Country (2026-2031)
10 South America by Country
10.1 South America Virus like Particle (VLP) Vaccines Sales by Country
10.1.1 South America Virus like Particle (VLP) Vaccines Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.1.2 South America Virus like Particle (VLP) Vaccines Sales by Country (2020-2025)
10.1.3 South America Virus like Particle (VLP) Vaccines Sales Forecast by Country (2026-2031)
10.2 South America Virus like Particle (VLP) Vaccines Market Size by Country
10.2.1 South America Virus like Particle (VLP) Vaccines Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2.2 South America Virus like Particle (VLP) Vaccines Market Size by Country (2020-2025)
10.2.3 South America Virus like Particle (VLP) Vaccines Market Size Forecast by Country (2026-2031)
11 Middle East and Africa by Country
11.1 Middle East and Africa Virus like Particle (VLP) Vaccines Sales by Country
11.1.1 Middle East and Africa Virus like Particle (VLP) Vaccines Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.1.2 Middle East and Africa Virus like Particle (VLP) Vaccines Sales by Country (2020-2025)
11.1.3 Middle East and Africa Virus like Particle (VLP) Vaccines Sales Forecast by Country (2026-2031)
11.2 Middle East and Africa Virus like Particle (VLP) Vaccines Market Size by Country
11.2.1 Middle East and Africa Virus like Particle (VLP) Vaccines Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2.2 Middle East and Africa Virus like Particle (VLP) Vaccines Market Size by Country (2020-2025)
11.2.3 Middle East and Africa Virus like Particle (VLP) Vaccines Market Size Forecast by Country (2026-2031)
12 Value Chain and Sales Channels Analysis
12.1 Virus like Particle (VLP) Vaccines Value Chain Analysis
12.1.1 Virus like Particle (VLP) Vaccines Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 Virus like Particle (VLP) Vaccines Production Mode & Process
12.2 Virus like Particle (VLP) Vaccines Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 Virus like Particle (VLP) Vaccines Distributors
12.2.3 Virus like Particle (VLP) Vaccines Customers
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.